Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Fig. 1

Overall (A, B) and progression-free (C, D) Kaplan-Meier survival curves for patients treated with nivolumab. After start of the nivolumab therapy, median overall survival (A) was 5.95 months and median progression-free survival (C) was 1.6 months. Patients who responded to nivolumab had significantly better overall survival (B) and progression-free survival (D) (p < 0.0001)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us